TY - JOUR
T1 - Androgen signaling in prostate cancer
AU - Dai, Charles
AU - Heemers, Hannelore
AU - Sharifi, Nima
N1 - Funding Information:
This work is supported by funding from the Howard Hughes Medical Institute Medical Fellows Program (C.D.), National Cancer Institute (CA166440 to H.H. and R01CA168899, R01CA172382, R01CA190289 to N.S.), Prostate Cancer Foundation (Young Investigator Award to H.H. and Challenge Award to N.S.), Howard Hughes Medical Institute Physician-Scientist Early Career Award (N.S.), American Cancer Society Research Scholar Award (12-038-01-CCE to N.S), and Department of Defense PCRP award W81XWH-16-1-0404 (H.H.).
Publisher Copyright:
© 2017 Cold Spring Harbor Laboratory Press.
PY - 2017/9
Y1 - 2017/9
N2 - The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.
AB - The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85025088881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025088881&partnerID=8YFLogxK
U2 - 10.1101/cshperspect.a030452
DO - 10.1101/cshperspect.a030452
M3 - Article
C2 - 28389515
AN - SCOPUS:85025088881
SN - 2157-1422
VL - 7
JO - Cold Spring Harbor Perspectives in Medicine
JF - Cold Spring Harbor Perspectives in Medicine
IS - 9
M1 - a030452
ER -